MINIMIZE RISK & UNCERTAINTY IN ONCOLOGY CLINICAL TRIALS

PROBLEM

LOW ONCOLOGY TRIAL PARTICIPATION

QTc DATA DETERMINES PATIENT

INCLUSION/EXCLUSION

oncologic agents prolong QTc

30-45%

ONLY 3% of oncology patients

participate in clinical trials

Most clinical trials set inclusion/exclusion and

FALSE therapy hold/terminate criteria

READINGS on QTc measures, but many

Marshall, MD, John L., Why Are Only 3% of US Cancer Patients in Clinical Trials? http://www.medscape.com/viewarticle/777662

RISKS ARISE FROM AVOIDABLE ERRORS



77% wrong QTc data Over/under-measures of site managed/paper ECGs = unnecessary withholding of treatment

Adverse event reporting QTc (increases) reported as adverse events

SITE[~]MANAGED ECG ANALYSIS CAN NEGATIVELY IMPACT TRIALS



> Excludes eligible patients

- >Extends recruiting
- > Jeopardizes patient safety

ERT: PROVIDING CONFIDENCE AT EVERY TURN

PROVEN ONCOLOGY TRIAL EXPERIENCE

- >91 regulatory approvals across 1,076 oncology studies
- > 35 oncology approvals within past 5 years
- > 180,000+ cancer patients
- > 25,000+ sites

DEEP ONCOLOGY TRIAL EXPERTISE

- > Tailored solutions for Phase I & II trials
- > Large-scale, global Phase III & IV expertise
- > Oncology experience across most indications and complex therapies

SOLUTIONS FOR ALL YOUR TRIAL NEEDS


Enhance Trial Oversight | Enable Site Optimization | Improve Patient Engagement | Ensure Safety & Measure Efficacy



SOLUTION

ECG CENTRALIZATION IN ONCOLOGY TRIALS LOWERS RISKS

ERT Cardiac Safety Solutions overcome ECG challenges and help to support enrollment, retention and safety goals.



Include more patients

30-45% patients who would be excluded from trials based on ECG machine measurements are actually eligible for inclusion



Withold fewer doses

Withholding medication based on ECG machine QTc measurements is actually unnecessary in most instances

APPROVE MORE POTENTIALLY LIFE[~]SAVING MEDICATIONS



ECG centralization with ERT:

- > Excludes fewer eligible patients
- Ensures patient safety
- > Reduces study duration and costs

Review full study results at ert.com/CSoncology

KEEPING YOUR TRIALS ON TRACK AND ON BUDGET

- > Reduce oncology site selection challenges, site burden and patient enrollment risks
- > Improve oncology trial operations and efficiencies
- > Enhance oncology data quality & increase outputs
- > Reduce timelines and boost approval rates
- > Provide the evidence you need to make your next move

errglobal in



